RPRX's Quality Score rose 1 point on Tue, Nov 10, to 17. Buying reached its highest in 20 days.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 171% over three years while the S&P 500 rose 80%.
“Net income attributable to the Legacy Investors Partnerships increased by $37.6 million in 2025 as compared to 2024”
| The company | Profit up 17x |
| Latest filing | 8-K, Nov 4 |
Tue Nov 17: UBS Global Biopharma Conference 2026Investor conference · date confirmed.
2 more dates ahead: the conference and dividend dates, for Pro members.
After its last 4 reports it closed +0.7% on average, higher 4 of 4 times.
Excellentfor quality, not price, 8 of 14 chart checks firingWhat the Quality Score means
RPRX is #14 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 14 |
Net income over four quarters: RPRX $672M, ONC $916M.
Expected to report Wed Feb 10, before the open (in 92 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The increase was primarily driven by Tremfya, Voranigo, Evrysdi and Imdelltra, partially offset by declines from Promacta due to U.S. generic competition and from Imbruvica.”
RPRX's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Interest paid | $350M to $360M |
“Payments for operating and professional costs in 2026 are expected to decrease as a percentage of Portfolio Receipts, compared to 8.9% in 2025, primarily due to extinguishment of the management fee following the completion of the internalization transaction on May 16, 2025.”
From its results filing (SEC filing · Nov 4)
Sales grew 2.3% a year over 5 years, fiscal 2020 to 2025.
Pays $0.94 a share a year.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 4, 2026 | -1.1% | +1.8% | +4.6% |
| Aug 5, 2026 | +3.6% | +0.5% | +0.5% |
| May 6, 2026 | +1.7% | +0.6% | +2.5% |
Sales grew in five of the last seven years, to $2.4B in 2025. It made a profit in each of the eight years.
RSI 77.8, MACD above signal, above both averages. Not scored.
One trade disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: RPRX is 0.1% of VYM and under 0.1% of DGRO, the most of the 24 funds Breakaway covers, by their holdings as filed for Jul 31, 2026.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
“We face competition from other parties that acquire biopharmaceutical royalties.”
RPRX scores 17 today, which Breakaway calls Excellent. It is #14 of 281 in Biotech by Quality Score, with 8 of 14 chart checks firing. Up 171% over three years while the S&P 500 rose 80%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
RPRX scores 17 today, which Breakaway calls Excellent (15 to 19). That is #14 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind RPRX's 17.
Expected to report Wed Feb 10, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. RPRX closed higher after 4 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.